New hope for Tough-to-Treat lymphoma: experimental combo targets cancer cells
NCT ID NCT05498220
Summary
This study tested a new combination of cancer drugs for people with an aggressive type of lymphoma (DLBCL) that has returned or did not respond to the first treatment. The goal was to see if adding a newer targeted drug (polatuzumab vedotin) to a standard chemotherapy mix could better control the disease. The trial involved a small group of patients to measure how well the treatment worked and how safe it was.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.